本页面由Tiger Trade Technology Pte. Ltd.提供服务

Can-Fite Biopharma Ltd

3.15
+0.01100.35%
成交量:1.00万
成交额:3.16万
市值:675.12万
市盈率:0.00
高:3.18
开:3.15
低:3.15
收:3.14
52周最高:36.40
52周最低:3.11
股本:214.25万
流通股本:210.50万
量比:1.73
换手率:0.48%
股息:- -
股息率:- -
每股收益(TTM):-1,791.0249
每股收益(LYR):-3,259.3317
净资产收益率:-178.24%
总资产收益率:-66.75%
市净率:1.21
市盈率(LYR):0.00

数据加载中...

2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/04

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/13

SEC问询函

CORRESP [Cover] - Correspondence
2021/08/26

招股说明书

Can-Fite BioPharma Ltd.
2021/08/26

招股说明书

F-1 - Registration statement for certain foreign private issuers
2021/03/25

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/16

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/09

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/01/29

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/11/30

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/10/07

SEC问询函

CORRESP [Cover] - Correspondence
2020/08/27

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/07/22

SEC问询函

CORRESP [Cover] - Correspondence
2020/07/10

招股说明书

F-1 - Registration statement for certain foreign private issuers
2020/06/19

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/19

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/01

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/13

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/07

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]